HUTCHMED (China) Limited Total Liabilities
HUTCHMED (China) Limited total liabilities. Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has total liabilities worth €501.83 Million EUR (≈ $586.70 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check H7T1 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of HUTCHMED (China) Limited (2016–2025)
Total liabilities of HUTCHMED (China) Limited from 2016 to 2025. This chart illustrates how HUTCHMED (China) Limited's total liabilities have evolved over time, based on quarterly financial data. Explore HUTCHMED (China) Limited (H7T1) long-term investment share to see how much of total assets are deployed in long-term investments.
HUTCHMED (China) Limited Competitors by Total Liabilities
The table below lists competitors of HUTCHMED (China) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank of Zhengzhou Co Ltd Class A
SHE:002936
|
China | CN¥686.82 Billion |
|
Happen, Inc. Common Stock
NASDAQ:HAPN
|
USA | $10.98 Billion |
|
Zenas BioPharma, Inc. Common Stock
NASDAQ:ZBIO
|
USA | $454.59 Million |
|
Lianhe Chemical Technology Co Ltd
SHE:002250
|
China | CN¥6.70 Billion |
|
Evertec Inc
NYSE:EVTC
|
USA | $1.76 Billion |
|
Chin Hin Group Bhd
KLSE:5273
|
Malaysia | RM3.24 Billion |
|
INOX India Limited
NSE:INOXINDIA
|
India | Rs-11.18 Billion |
|
Grupo Gigante S. A. B. de C. V
MX:GIGANTE
|
Mexico | MX$26.66 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down HUTCHMED (China) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is HUTCHMED (China) Limited's balance sheet.
Liquidity & Leverage Metrics
HUTCHMED (China) Limited Total Liabilities Ratios Explained
HUTCHMED (China) Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HUTCHMED (China) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HUTCHMED (China) Limited (2016–2025)
The table below shows the annual total liabilities of HUTCHMED (China) Limited from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €501.83 Million ≈ $586.70 Million |
-0.10% |
| 2024-12-31 | €502.34 Million ≈ $587.29 Million |
-6.35% |
| 2023-12-31 | €536.39 Million ≈ $627.09 Million |
+36.63% |
| 2022-12-31 | €392.57 Million ≈ $458.96 Million |
+17.84% |
| 2021-12-31 | €333.15 Million ≈ $389.48 Million |
+62.38% |
| 2020-12-31 | €205.17 Million ≈ $239.86 Million |
+34.79% |
| 2019-12-31 | €152.22 Million ≈ $177.96 Million |
+26.99% |
| 2018-12-31 | €119.86 Million ≈ $140.13 Million |
+6.11% |
| 2017-12-31 | €112.97 Million ≈ $132.07 Million |
-18.36% |
| 2016-12-31 | €138.38 Million ≈ $161.78 Million |
-- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more